UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 820

Sortiert nach

Antibody drug conjugates: lessons from 20 years of clinical experience

Annals of oncology, 2016-12, Vol.27 (12), p.2168-2172

Tolcher, A.W.

2016

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Annals of oncology, 2016-10, Vol.27 (10), p.1928-1940

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Annals of oncology, 2016-03, Vol.27 (3), p.526-532

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of oncology, 2015-01, Vol.26 (1), p.58-64

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

Annals of oncology, 2012-04, Vol.23 (4), p.968-973

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Annals of oncology, 2010-02, Vol.21 (2), p.376-381

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

British journal of cancer, 2017-11, Vol.117 (11), p.1592-1599

2017

Link zum Volltext

Verfügbarkeit prüfen

Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 + T cell responses

Nature communications, 2018-02, Vol.9 (1), p.633-13, Article 633

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i2

2019

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

British journal of cancer, 2011-09, Vol.105 (7), p.938-944

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii409-viii409

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

British journal of cancer, 2014-07, Vol.111 (2), p.272-280

2014

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii138

2018

Link zum Volltext

Verfügbarkeit prüfen

362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

European journal of cancer (1990), 2015-09, Vol.51, p.S74-S75

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii144

2018

Link zum Volltext

Verfügbarkeit prüfen

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii294-viii294

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO open, 2024-04, Vol.9 (4), p.102961-102961, Article 102961

2024

Link zum Volltext

Verfügbarkeit prüfen

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Cancer chemotherapy and pharmacology, 2012-08, Vol.70 (2), p.305-313

2012

Link zum Volltext

Verfügbarkeit prüfen

Development and characterization of HER2+ T-DM1-resistant breast cancer PDX models

European journal of cancer (1990), 2016-12, Vol.69, p.S59-S59

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Annals of oncology, 2013-03, Vol.24 (3), p.784-791

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.478-484

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Annals of oncology, 2013-04, Vol.24 (4), p.1104-1111

2013

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

Blood, 1997-07, Vol.90 (1), p.244-251

1997

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α₅β₁ integrin monoclonal antibody (volociximab) in cancer patients

Cancer chemotherapy and pharmacology, 2010, Vol.65 (2), p.207-217

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 820

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(797)
Mit Volltextzugriff
(781)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(820)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(223)
Humans
(219)
Life Sciences & Biomedicine
(219)
Oncology
(169)
Female
(166)
Middle Aged
(139)
Male
(131)
Adult
(128)
Aged
(126)
Biological And Medical Sciences
(118)
Medical Sciences
(116)
Neoplasms - Drug Therapy
(107)
Pharmacology. Drug Treatments
(95)
Tumors
(90)
Antineoplastic Agents
(87)
Dose-Response Relationship, Drug
(59)
Aged, 80 And Over
(55)
Treatment Outcome
(53)
Hematology, Oncology And Palliative Medicine
(50)
Neoplasms - Pathology
(46)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Antibody drug conjugates: lessons from 20 years of clinical experience

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 + T cell responses

A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies

362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Development and characterization of HER2+ T-DM1-resistant breast cancer PDX models

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α₅β₁ integrin monoclonal antibody (volociximab) in cancer patients

Suchergebnisse filtern